A Randomized, Double-blind, Parallel, Single-dose, Phase 1 Clinical Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of GS101 Versus Dupixent® After Subcutaneous Injection
Latest Information Update: 08 Mar 2026
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Jiangsu Genscend Biopharma
Most Recent Events
- 22 Feb 2026 New trial record